How are these compounds
scientifically different?
Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.
This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.
Target & Mechanism Comparison
Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.
← Scroll to see all compounds →
| Target | Selank | Semax |
|---|---|---|
| ✓ | — | |
| — | ✓ |
What These Compounds Share
Key Differences
Compound Detail
Selank
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
Heptapeptide · 7 amino acids · Synthetic analogue of tuftsin
Tap a target above for a plain-language explanation.
Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.
View Research Sources (3) →
Russian clinical trial literature, head-to-head vs. phenazepam. Selank showed pronounced anxiolytic and mild nootropic effects, persisting up to a week after the last dose.
Supports: experimental_research, human_administration_status
Randomized, head-to-head vs. medazepam. Anxiolytic effects similar between arms; Selank additionally showed antiasthenic and psychostimulant effects. Reduced leu-enkephalin half-life correlated with disease severity and improved with Selank treatment.
Supports: experimental_research, human_administration_status
NOT a head-to-head Selank-vs-phenazepam comparison -- this tests Selank as an add-on to phenazepam vs. phenazepam alone. Combination produced earlier improvement and reduced phenazepam's side effects (attention/memory impairment, sedation, sexual disturbance) both during and after tranquilizer withdrawal.
Supports: experimental_research
Semax
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
Heptapeptide · 7 amino acids · Synthetic analogue of an ACTH fragment
Tap a target above for a plain-language explanation.
Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.
View Research Sources (2) →
Russian clinical trial literature. Semax added to intensive therapy increased regression of general cerebral and focal (especially motor) neurological deficits, assessed via clinical scales, EEG mapping and somatosensory evoked potentials. Most effective doses 12-18 mg/day for 5-10 days.
Supports: research_areas, human_administration_status
Russian clinical trial literature. Semax increased plasma BDNF regardless of rehab timing; higher BDNF correlated with better Barthel Index outcomes, and earlier rehab correlated with better motor recovery.
Supports: research_areas, mechanism_summary
Common Research Comparisons
Frequently studied groupings — not recommendations.
Browse more compounds
5-Amino-1MQ
NNMT inhibitor
BPC-157
Gastric pentadecapeptide
Cagrilintide
Long-acting amylin analogue
CJC-1295
Modified GHRH analogue
DSIP
Neuropeptide
Epithalon
Synthetic tetrapeptide
GHK-Cu
Copper-binding tripeptide
GHRP-2
GH-releasing peptide / GH secretagogue
Glutathione
Endogenous antioxidant tripeptide
HCG
Glycoprotein hormone
IGF-1 LR3
IGF-1 receptor agonist (engineered analogue)
Ipamorelin
GH secretagogue
Kisspeptin-10
Kisspeptin fragment
KPV
α-MSH-derived tripeptide
Melanotan I
α-MSH analogue
Melanotan II
Cyclic melanocortin agonist
MOTS-c
Mitochondrial-derived peptide
NAD+
Cellular redox cofactor
PT-141
Cyclic melanocortin receptor agonist
Retatrutide
Triple receptor agonist
rHGH (Somatropin)
Growth hormone receptor agonist
Selank
Synthetic tuftsin analogue
Semaglutide
GLP-1 receptor agonist
Semax
Synthetic ACTH-fragment analogue
Sermorelin
GHRH fragment analogue
SS-31
Mitochondria-targeting tetrapeptide
Tesamorelin
Stabilised GHRH analogue
Thymosin Alpha-1
Thymic peptide
Thymosin Beta-4 (TB-4)
Thymosin Beta-4
Tirzepatide
Dual incretin receptor agonist